ClinicaliQ Trial Snapshot
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56 — Active Not Recruiting • Phase III • NCT06683742.
- Two-year trial testing EYP-1901 against aflibercept for wet age-related macular degeneration, with main results at one year.
Verify eligibility, endpoints and current status on the original ClinicalTrials.gov registry before acting on this summary.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This is a phase 3 randomized, double -masked study comparing the efficacy of EYP-1901 against Aflibercept. Conditions: Wet Age Related Macular Degeneration, wAMD Interventions: EYP-1901, Aflibercept (2.0 mg) Lead Sponsor: EyePoint Pharmaceuticals, Inc. Planned Enrollment: 400 participants